
Conflict of interest statement: Competing interests: AB declares the following
relationship with commercial entities developing therapeutics for HBV treatment. 
He collaborates and receives research support from Gilead Sciences to test the
effect of HBV antigens on immune cell function. He acted as a consultant and
served on the advisory boards of Gilead Sciences, MedImmune, Jansseen-Cilag,
IONIS, Abivax, HUMABS BioMed. AB is also a cofounder of LION TCR pte. ltd. a
biotech company developing T cell receptors for treatment of virus-related
cancers and chronic viral diseases.


6. Gut. 2018 May;67(5):988. doi: 10.1136/gutjnl-2017-315603. Epub 2017 Nov 25.

Prognosis of immune-tolerant phase chronic hepatitis B.

Chu CM(1), Liaw YF(1).

Author information: 
(1)Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University
College of Medicine, Taipei, Taiwan.

Comment in
    Gut. 2018 May;67(5):988-989.

Comment on
    Gut. 2018 May;67(5):945-952.

DOI: 10.1136/gutjnl-2017-315603 
PMID: 29175863  [Indexed for MEDLINE]
